Transfusion Medicine/Hemostasis Clinical Trials Network

描述(由申请人提供) 输血医学和止血临床试验网络(TMH CTN)成立于2002年，是为了满足在输血医学和止血方面进行大型多机构临床试验的需要。TMH网络是促进输血医学和止血领域知识和理解的国家资源。该网络将促进对对患有止血疾病的儿童和成人的潜在益处的新管理战略进行有效比较；还将评估用于治疗血液病的新的和现有的血液疗法和细胞因子。自成立以来，17个资助地点的主要研究人员和他们的合作者成功地在这些领域开发和实施了临床试验。在迄今进展的基础上，TMH CTN建议在未来5年内：1)维持并根据需要进一步发展一个结构，以支持在输血医学和止血领域开发、实施和进行临床试验。这将与新英格兰研究所作为数据协调中心和NHLBI的项目工作人员合作完成。2)利用工作和研究监督小组委员会的结构，完成正在进行的试验，并开发、完善和完成本申请中提议的新试验。3)发展合作关系和支持培训机会，以促进拟议的临床试验的成功，并促进输血医学和止血领域的进一步发展。北卡罗来纳大学教堂山分校是17个资助地点之一，一直积极参加TMH CTN。马克·布雷彻博士(病理和实验室系)是北卡罗来纳大学的首席研究员。奈杰尔·基博士(医学部-血液科)是联合首席研究员。他们两人都积极参加了TMH CTN的几个小组。他们还定期出席督导委员会的季度会议。额外的TMH研究人员包括两名全职研究护士和一名兼职医疗技术员。北卡罗来纳大学正在进行两个TMH CTN协议，该站点的调查人员打算在未来支持新的网络协议。 北卡罗来纳大学教堂山评论

DESCRIPTION (provided by applicant) The Transfusion Medicine and Hemostasis Clinical Trial Network (TMH CTN) was funded in 2002, in response to a demonstrated need for large multi-institutional clinical trials in transfusion medicine and hemostasis. The TMH Network is a national resource for the advancement of knowledge and understanding in the field of transfusion medicine and hemostasis. The Network will promote the efficient comparison of novel management strategies of potential benefit for children and adults with hemostatic disorders; and will also evaluate novel as well as existing blood therapies and cytokines for the treatment of hematologic disorders. Since its inception, the principal investigators and their collaborators at the 17 funded sites, have worked successfully to develop and implement clinical trials in these areas. Building on the progress to date, over the next the 5 years, the TMH CTN proposes to: 1) Maintain, and further develop, as needed, a structure to support the development, implementation and conduct of clinical trials in the areas of transfusion medicine and hemostasis. This will be done in collaboration with the New England Research Institutes as Data Coordinating Center, and program staff at NHLBI. 2) Utilizing a structure of working and study oversight subcommittees, complete ongoing trials and develop, refine and complete new trials proposed in this application. 3) Develop collaborative relationships and support training opportunities to facilitate the success of the proposed clinical trials and further the fields of transfusion medicine and hemostasis. The University of North Carolina at Chapel Hill, one of 17 funded sites, has been participating actively in the TMH CTN. Dr. Mark Brecher (Department of Pathology and Laboratory) is the lead principal investigator at UNC. Dr. Nigel Key (Department of Medicine- Hematology Division) is the co-principal investigator. Both of them have actively participated in several subgroups of TMH CTN. They also regularly attend the quarterly Steering Committee meetings. Additional TMH study staff includes two full-time research nurses and one part-time medical technologist. Two TMH CTN protocols are ongoing at UNC, and it is the intention of the investigators at this site to support new network protocols in the future. UNIVERSITY OF NORTH CAROLINA CHAPEL HILL CRITIQUES